P38 Mapk Gamma And Delta For Use As Biomarkers Of Nafld

Full-text?

The full document isn't yet available to us from the patent office.

Abstract

p38 MAPK gamma and delta for use as biomarkers of NAFLD. The present invention provides an in vitro method for prognosis and diagnosis NAFLD, preferably for hepatic steatosis. The method of the invention is based on blood samples and consequently it may be considered as a non-invasive test for diagnosis of hepatic steatosis. Blood levels of p38 mapk gamma and delta are therefore used as biomarkers of hepatic steatosis in human.


Claims

Information currently unavailable.

Download PDF
Document Preview
Document History
  • Publication: Oct 23, 2013
  • Application: Apr 19, 2012
    EP EP 12164807 A
  • Priority: Apr 19, 2012
    EP EP 12164807 A

Download Citation


Sign in to the Lens

Feedback